ArticleInfectious agents and cancer2017
The effects of antiviral treatment on breast cancer cell line.
Article in Infectious agents and cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 40 citations in OpenAlex.
- Neuritogenic effects of Ulva lactuca aqueous extract on Neuro-2a cells.BMC complementary medicine and therapies · 2026Article
- Novel Dorsomorphin Derivatives: Molecular Modeling, Synthesis, and Bioactivity Evaluation.Biomolecules · 2026Article
- Abacavir enhances the efficacy of doxorubicin via inhibition of histone demethylase KDM5B in breast cancer.Scientific reports · 2025Article
- Impact of pH-Responsive Cisplatin/Ribavirin-Loaded Monodispersed Magnetic Silica Nanocomposite on A549 Lung Cancer Cells.Pharmaceutics · 2025Article
- Remission of HPV-Related Diseases by Antivirals for Herpesvirus: Clinical Cases and a Literature Review.Viruses · 2024Review
- Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance.Genes & diseases · 2024Review
- Impact of oseltamivir on the risk of cancer.Frontiers in oncology · 2024Article
- Microbes, macrophages, and melanin: a unifying theory of disease as exemplified by cancer.Frontiers in immunology · 2024Review
- Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.European journal of medical research · 2023Review
- Associations of Head and Neck Cancer with Hepatitis B Virus and Hepatitis C Virus Infection.Cancers · 2023Article
- Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities.Molecular pharmaceutics · 2023Review
- Development of a Novel Red Clay-Based Drug Delivery Carrier to Improve the Therapeutic Efficacy of Acyclovir in the Treatment of Skin Cancer.Pharmaceutics · 2023Article
- Tumor resident, TRA anti-viral CDR3 chemical sequence motifs are associated with a better breast cancer outcome.Genes and immunity · 2023Article
- Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline-a review.Journal of the Egyptian National Cancer Institute · 2022Review
- Evaluation of the Effects of Favipiravir Combined with Vitamin C on Alveolar Bone in Rats.Journal of evolutionary biochemistry and physiology · 2022Article
- Exploring the selectivity of guanine scaffold in anticancer drug development by computational repurposing approach.Scientific reports · 2021Article
- A Novel Long Non-Coding RNA lnc030 Maintains Breast Cancer Stem Cell Stemness by Stabilizing SQLE mRNA and Increasing Cholesterol Synthesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Drug Repurposing in Medulloblastoma: Challenges and Recommendations.Current treatment options in oncology · 2020Review
- Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells.Journal of cellular and molecular medicine · 2020Article
- Selected nucleos(t)ide-based prescribed drugs and their multi-target activity.European journal of pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies have revealed the positive antiproliferative and cytotoxic effects of antiviral agents in cancer treatment. The real effect of adjuvant antiviral therapy is still controversial due to the lack of studies in biochemical mechanisms. Here, we studied the effect of the antiviral agent acyclovir on morphometric and migratory features of the MCF7 breast cancer cell line. Molecular levels of various proteins have also been examined.
methodsTo evaluate and assess the effect of antiviral treatment on morphometric, migratory and other cellular characteristics of MCF7 breast cancer cells, the following experiments were performed: (i) MTT assay to measure the viability of MCF7 cells; (ii) Colony formation ability by soft agar assay; (iii) Morphometric characterization by immunofluorescent analysis using confocal microscopy; (iv) wound healing and transwell membrane assays to evaluate migration and invasion capacity of the cells; (v) ELISA colorimetric assays to assess expression levels of caspase-3, E-cadherin and enzymatic activity of aldehyde dehydrogenase (ALDH).
resultsWe demonstrate the suppressive effect of acyclovir on breast cancer cells. Acyclovir treatment decreases the growth and the proliferation rate of cells and correlates with the upregulated levels of apoptosis associated cytokine Caspase-3. Moreover, acyclovir inhibits colony formation ability and cell invasion capacity of the cancer cells while enhancing the expression of E-cadherin protein in MCF7 cells. Breast cancer cells are characterized by high ALDH activity and associated with upregulated proliferation and invasion. According to this study, acyclovir downregulates ALDH activity in MCF7 cells.
conclusionsThese results are encouraging and demonstrate the possibility of partial suppression of cancer cell proliferation using an antiviral agent. Acyclovir antiviral agents have a great potential as an adjuvant therapy in the cancer treatment. However, more research is necessary to identify relevant biochemical mechanisms by which acyclovir induces a potent anti-cancer effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.